The mean age $\pm$ SD was 57.1 $\pm$ 16.1 years. The mean evolution of RA was 9 $\pm$ 5.8 years. The patients had previously received the following DMARDs; MTX (n=12), leflunomide (LFN) (8) sulfasalazine (SSZ) (3) hydroxychloroquine (HCQ) (1) azathioprine (AZA) (2), gold salts (2). In addition, 11 patients had previously received biological drugs: adalimumab (4) anakinra: (1), etanercept (4), rituximab (4), infliximab (1), certolizumab (1), abatacept (1). RA was seropositive in 11 cases (92%). Besides HRCT, the diagnosis of ILD was confirmed by biopsy in 4 patients. In 2 patients ILD was drug-related: MTX (n=2). TCZ was prescribed in monotherapy (n=8) or combined with other DMARDs (4). These DMARDs were: LFN (2), MTX (1), AZA (1). In many patients the dyspnea and DLCO remain stable (Table). After a follow-up of 12 months, 2 patients withdrew TCZ, 1 patient for ILD worsening and 1 patient for joint inefficacy.

Table 1

	Baseline	3th month	6 th month	12th month
MRC, n (%)		11	8	11
- No change		11 (100)	7 (87)	8 (73)
- Improvement		0	0	2 (18)
- Worsening		0	1 (13)	1 (9)
FCV, n (%)		2	5	9
- No change		2 (100)	5 (100)	6 (67)
- Improvement		0	0	2 (23)
- Worsening		0	0	1 (12)
DLCO, n (%)		2	4	9
- No change		1 (50)	3 (75)	9 (100)
- Improvement		0	0	0
- Worsening		1 (50)	1 (25)	0
HRTC, n (%)		0	2	10
- No change		1 (50)	7 (70)	
- Improvement		0	0	
- Worsening		1 (50)	3 (30)	
DAS28 - mean	4.46 $\pm$ 1.40	3.35 $\pm$ 1.19	3.23 $\pm$ 1.04	2.98 $\pm$ 0.95
CRP (mg/dl) - mean	3.23 $\pm$ 2.96	1.11 $\pm$ 0.98	1.48 $\pm$ 0.95	1.15 $\pm$ 0.84
ESR (mm/1st h) - mean	45.17 $\pm$ 28.84	16.16 $\pm$ 10	16.16 $\pm$ 11.41	17.47 $\pm$ 25.45

Conclusions: In our knowledge, this is the largest series that assess the EPID associated with RA treated with TCZ. We observed that in many cases pulmonary involvement remains stable.

References:

- [1] Kobayashi J et al. Chest 1995; 108: 311.
- [2] Kawashiri SY et al. Rheumatol Int 2012; 32: 4023-6.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3580

THU0135 THE COURSE OF LOWER EXTREMITY FUNCTION IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS OVER THE FIRST FIVE YEARS

M. Mellblom Bengtsson¹, C. Book^{1,2}, S. Hagel^{3,4}, L.T. Jacobsson⁵, C. Turesson^{1,2}. ¹Department of Rheumatology, Skåne University Hospital; ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö; ³Rheumatology, Department of Clinical Sciences, Lund, Lund University; ⁴Department of Rheumatology, Skåne University Hospital, Lund; ⁵Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden

Background: Rheumatoid arthritis (RA) frequently involves joints of the feet and the knees. Disability related to arthritis in the lower extremities has a major impact in many patients, but has not been extensively studied.

Objectives: To investigate lower extremity function in early RA, using validated tests, and to assess its relation to other disease parameters.

Methods: Consecutive patients with early RA (symptom duration $\leq$ 12 months) in an inception cohort from a well-defined area were followed according to a structured protocol, with visits at inclusion and after 1, 2 and 5 years. Lower extremity function was investigated using the Index of Muscle Function (IMF) (1), a validated battery of tests by which the patient's general ability, muscle strength, muscular endurance and balance/coordination are assessed by a physiotherapist. The scores on the subscales are added for a total IMF score (IMF total) of 0-40. A subscore of the Health Assessment Questionnaire Disability Index (HAQ-DI), based on the 10 questions that are mainly dependent on function of the lower extremities (the HAQ-DI-LE (2)) was calculated, as well as a modified HAQ-DI-LE (mHAQ-DI-LE) that included only the three HAQ-DI domains in which all questions relate mainly to the lower extremities. Changes in the IMF total score and subscore scores between visits were analyzed using the Wilcoxon signed rank test. Correlations between disease parameters were assessed using Spearman's rank test.

Results: A total of 106 patients (67% women, mean age 61 years, mean baseline DAS28 4.4, median baseline HAQ-DI 0.75) were included. Data on IMF total were available for 100, 89 and 67 patients at the 1, 2 and 5-year visits. Lower extremity function improved from baseline to the 1-year visit (IMF total median 10; interquartile range (IQR) 4-16 vs. 7; IQR 3-12) ($p=0.01$). This was followed by a decline in lower extremity function, in particular between the 2-year and 5-year visits (IMF total median 8 (IQR 3-13) vs 9.5 (IQR 3.75-18.25); $p=0.001$). This was mainly due to worsening in test results for muscle strength (median 4 (IQR 1-6) vs 5 (IQR 2-9); $p=0.001$) and for balance/coordination (median 2 (IQR 0-4) vs 3 (IQR 2-6); $p=0.001$). At baseline, IMF total correlated with HAQ-DI-LE

($r=0.46$), mHAQ-DI-LE ($r=0.49$) and HAQ-DI ($r=0.40$) (all $p<0.001$), whereas there were weaker correlations with CRP ($r=0.24$; $p=0.02$) and DAS28 ($r=0.28$; $p=0.004$). There were consistent correlations between IMF total and HAQ-DI-LE, mHAQ-DI-LE and HAQ-DI at all time points, but no significant correlations for IMF total with CRP and DAS28 at the 2-year visit.

Conclusions: In early RA, there was improvement in lower extremity function during the first year, followed by a gradual decline, possibly explained by lack of complete disease control and aging. Tests of muscular function in the lower extremities may reveal aspects of RA disease severity that are not fully captured by standard disease activity measures, and may add important information regarding functional loss.

References:

- [1] Ekdahl et al. Advances in Physiotherapy 1999; 1: 45-55.
- [2] Ekdahl et al. J Clin Epidemiol 1989; 42: 947-54.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4223

THU0136 NESFATIN-1 EXPRESSION IS ASSOCIATED WITH REDUCED ATHEROSCLEROTIC DISEASE RISK IN PATIENTS WITH RHEUMATOID ARTHRITIS

C. Robinson¹, L. Tsang¹, A. Solomon¹, A. Woodiwiss¹, S. Gunter¹, H.-C. Hsu¹, G. Norton¹, A. Millen¹, P. Desseine^{1,2}. ¹Cardiovascular Pathophysiology and Genomic Research Unit, School of Physiology, University of the Witwatersrand, Johannesburg, South Africa, Johannesburg, South Africa; ²Rheumatology Division, Universitair Hospital Brussel, Brussels, Belgium

Background: Nesfatin-1 comprises a peptide that is involved in appetite suppression, energy homeostasis and fluid regulation, and was recently documented to participate in a range of cardiometabolic pathways (1,2). There is currently a need for the identification of novel biomarkers in the elucidation of CVD risk and its stratification in persons with rheumatoid arthritis (RA). The role of nesfatin-1 in cardiovascular disease risk among RA patients is uncertain.

Objectives: We investigated the potential impact of nesfatin-1 on subclinical cardiovascular disease manifestations in patients with RA by determining the associations of nesfatin-1 concentrations with atherosclerosis and circulating levels of matrix metalloproteinase (MMP)-2 that mediates plaque stability and those of MMP-3 and MMP-9 that cause plaque vulnerability.

Methods: Nesfatin-1 concentrations were measured in 236 (114 black; 122 white) RA patients. Relationships of nesfatin-1 concentrations with ultrasound determined carotid intima-media thickness (cIMT) and plaque and MMP levels were identified in confounder adjusted multivariate regression models.

Results: Nesfatin-1 concentrations were inversely associated with c-IMT (β (SE) = -0.022 (0.008), $p=0.00$) and directly with MMP-2 levels (β (SE) = 0.117 (0.031), $p=0.00$). After adjustment for conventional risk factors and RA characteristics, these associations persisted (c-IMT: β (SE) = -0.017 (0.008), $p=0.04$; MMP-2: β (SE) = 0.116 (0.033), $p=0.00$). Patient characteristics did not influence the nesfatin-1-to-cIMT relation (interaction $p\geq 0.7$). By contrast, the Disease Activity Score in 28 joints (DAS28) and Clinical Disease Activity Index impacted the nesfatin-1-to-cIMT association (interaction $p=0.04$ and 0.02, respectively). Nevertheless, in stratified analysis, nesfatin-1 concentrations were related to those of MMP-2 in patients with no or mild (β (SE) = -0.148 (0.054), $p=0.00$) and moderate or high disease activity (β (SE) = -0.086 (0.041), $p=0.04$) as determined by DAS28 (cut-off value 3.6) as well as by CDAI (cut-off value =10) (β (SE) = -0.130 (0.048), $p=0.00$ and 0.107 (0.046), $p=0.02$), respectively.

Conclusions: Nesfatin-1 concentrations are consistently associated with a reduced atherosclerosis burden and increased MMP-2 levels in patients with RA.

References:

- [1] Oh-I S, Shimizu H. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature. 2006;443:709-712.
- [2] Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: functions and physiology of a novel regulatory peptide. Journal of Endocrinology. 2016; e-pub ahead of print: doi: 10.1530/JOE-16-0361.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4595

THU0137 IMPACT OF PERIODONTAL AND RHEUMATIC DISEASE MARKERS ON FIRST-DEGREE RELATIVES OF PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO AGE GROUP

C. Romero-Sanchez^{1,2}, S. Giraldo³, J. De-Avila¹, M.A. Cano-Bermudez¹, L. Chila-M.¹, J. Bello-Gualtero², P. Chalem⁴, W. Bautista³, J. Londono⁵, C. Pacheco-Tena⁶, G. Lafaurie¹, R. Valle-Oñate⁷. ¹Unit of Oral Basic Investigation/School of Dentistry, Universidad El Bosque; ²Department of Rheumatology and Immunology, Hospital Militar Central, Bogotá, Colombia; ³School of Medicine, Universidad Militar Nueva Granada; ⁴Departamento de Reumatología, Fundación Instituto de Reumatología Fernando Chalem, Bogotá D.C.; ⁵Spondyloarthropathy Group, Rheumatology Universidad de la Sabana, Chia, Colombia; ⁶Departamento de Reumatología, Investigación y Biomedicina S.C., Chihuahua, Mexico; ⁷Departamento de Reumatología, Hospital Militar Central, Bogotá, Colombia, Bogotá D.C., Colombia

Background: Rheumatoid arthritis (RA) and periodontal disease (PD) have

similar underlying pathologic processes and share a general deregulation of the inflammatory response.

Objectives: To evaluate PD markers in first-degree relatives (FDR) of consanguinity individuals of patients with rheumatoid arthritis to compared with controls and to establish an association to rheumatic activity according to age groups

Methods: 201 FDR individuals and 201 matched controls were included. Clinical evaluation of rheumatologic and periodontal condition was performed. *P. gingivalis*, *P. gingivalis* IgG1 and IgG2, ESR, CRP, RF, ACPAs, painful and swollen joints were assessed. A frequencies analysis, comparisons and a logistic regression model were made. The study was approved by local ethics committee.

Results: 37.3% of patients with overweight and 10.1% obsesses. Subjects with more than one swelling joint were 21 subjects <30 years, 5 between 31–40, 5 between 41 to 50 subjects and 9 subjects over 50, for more one painful joint were 73. The RF was present in 8.0%, ACPA in 13%, RA33 in 1%. 67.3% had a diagnosis of PD, 81.6% had a moderate-severe $p=0.003$. *P. gingivalis* was in 47.9%, and *P. gingivalis* IgG1 were in 54.7%. It was evidenced that 25.3% patients presented BMI>30, where 81.8% had periodontitis $p=0.006$. Regression analysis on the whole group shows a risk to present BMI>25 (OR 1.67 IC-95% 1.02 – 2.74 $p=0.042$), ACPAs (OR 3.7 IC-95% 1.34–10.22 $p=0.012$), at least one pain joint (OR2.51 IC-95% 1.42–4.44 $p=0.001$) and gingival index (OR4.57 IC-95% 1.76–11.80 $p=0.002$) in FDR individuals. Based on age the risk to develop PD was increasing: individuals among 30 to 40 years shows OR 2.76 (IC-95% 1.24–6.18, $p=0.013$); among 41 to 50 years, OR 4.72 (IC-95% 1.81–12.32, $p=0.001$); and for >50 years individuals an OR 6.22 (IC-95% 2.55–15.1, $p=0.0001$). The discriminating analysis by age rank shows that FDR individuals <30 years ($n=67$) exhibited high risk to have at least one pain joint (OR 3.84 IC-95% 1.28–11.47 $p=0.016$). In subjects among 30 to 40 years ($n=46$), the risk was associated with periodontal pocket (OR1.44 IC-95% 1.05–4.98 $p=0.021$), one or more pain joint (OR 3.56 IC-95% 1.22–10.40 $p=0.020$) which it was maintained until 50 years individuals ($n=35$) (OR4.32 IC-95% 1.11–16.78 $p=0.0034$), individuals >50 years ($n=53$) show high risk to present BMI>25 (OR 4.00 IC-95% 1.46–10.45 $p=0.007$).

Conclusions: Obesity, ACPA and periodontitis can be considered as relevant conditions associated with the development of RA in FDRs. However, the analysis based on age group shows that periodontal markers do not appear early in FDR individuals; however, clinical rheumatologic variables are manifested and maintained over time.

References:

[1] Bello-Gualtero JM et al. J Periodontol 2016;87:346–356.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.5500

THU0138 DAS 28 CORRELATED POORLY WITH THE OBJECTIVE EVIDENCE OF INFLAMMATION AS DETECTED BY ULTRASOUND (US) EXAMINATION OF HANDS AND FEET IN PATIENTS WITH ESTABLISHED RHEUMATOID ARTHRITIS (RA)

C. Ciurtin, G. Brown, A. Cotton, J. Guinto, A. Jones, V. Morris. *Department of Rheumatology, University College London NHS Trust, London, United Kingdom*

Background: The Disease Activity Score including 28 joint count (DAS-28) is the most widely used outcome measure in RA. However, despite evidence that metatarsophalangeal (MTP) joints are often the first joints affected in RA, DAS-28 score does not incorporate them.

Objectives: Our study aimed to investigate the correlation between DAS-28 assessment and objective evidence of active joint inflammation using the US examination of both hands and feet, including wrists, metacarpophalangeal (MCP), proximal interphalangeal (PIP), and MTP joints.

Methods: A retrospective study was conducted, including 87 patients who were referred to the US clinic for an examination of their hands and feet in the last 6 months (46 patients with RA and 43 controls - patients with other inflammatory or degenerative arthropathies). Information about demographics, disease duration, current treatment, inflammatory markers, and DAS-28 scores was captured. The US OMERACT criteria were used for grading synovial hypertrophy, and assessing for the presence of Power Doppler (PD) signal, erosions and osteophytes. Statistical analysis methods included T-test, Mann-Whitney U test, Z score for proportions and Spearman's correlation coefficients.

Results: In the RA group, DAS-28 had a weakly positive correlation with the cumulative PD scores of their hands and feet joints ($R=0.14$, $P=0.02$), but did not correlate with PD score of MTP joints ($R=0.03$, $P=0.09$). In the control group, DAS-28 did not correlate significantly with either the total PD scores of feet ($R=0.42$, $P=0.26$) or hands and feet joints ($R=0.5$, $P=0.25$). Sensitivity of US examination of hands alone compared to hands and feet was 74.3% for the RA group, while the sensitivity of US feet to detect the presence of PD was 59.2% when compared to the US of both hands and feet.

Conclusions: We found that DAS-28 correlated poorly with objective evidence of inflammation as detected by US of the hands and feet, and this correlation was lost when only the presence of inflammation in the feet was taken into consideration. Further validation of our results in a larger study including patients stratified based on the disease duration might help understand which patient subgroups are more likely to have their disease activity significantly under-evaluated using DAS-28 outcome measure.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.3308

THU0139 DEPRESSIVE SYMPTOMS AND VITAMIN D IN PATIENTS WITH EARLY ARTHRITIS

D. Freier¹, M. Biersack¹, J. Detert¹, G.-R. Burmester¹, R. Uebelhack², T. Braun¹, V. Hoehne-Zimmer¹. ¹Rheumatology; ²Psychiatry, Charité-University Medicine, Berlin, Germany

Background: There is a high prevalence of depression in patients with rheumatic disorders. Especially, in rheumatoid arthritis, it is one of the most prevalent co-morbidities with 16% to 38%. Vitamin D (VD) deficiency is one of the known risk factors for depressive disorders. On the other hand, a VD deficiency has often been detected in rheumatic diseases. A possible correlation between these two co-morbidities has not been investigated so far in patients with early arthritis (EA).

Objectives: The aim of this study was to examine the association between VD deficiency and depression and/or anxiety disorders in patients who have presented themselves for the first time in the EA clinic.

Methods: Patients with a suspected EA (at least one swollen joint without previous trauma or joint infection with a symptom duration of 6 weeks to 12 months) received a screening date within five work days. The VD status (25-hydroxy-VD₃) was obtained during the first EA clinic consultation. In addition, each patient completed questionnaires on the disease history, as well as evaluated self-assessment questionnaires including the health assessment questionnaire (HAQ) and the Hospital Anxiety and Depression Scale (HADS). The hereby-obtained results of disease activity, VD-status and HADS-scores were investigated. In the observation period from June 2012 to March 2015, 75 patients fulfilled the inclusion criteria of completed results and questionnaires as well as a disease duration of less than 12 months.

Results: The mean age of this EA cohort was 51.7±16.9 years (q 65.3%, mean disease duration: 4.0±3.0 months). The prevalence of VD deficiency (<75 nmol/l) was 73.3%. 48.0% of EA patients showed a positive global distress score (≥ 13). The mean HADS global distress score in VD sufficient patients was 10.2±8.6 vs 13.3±6.9 in deficient patients. The observed difference was not statistically significant. There was neither an association between gender, age and VD status nor was there any difference in the laboratory parameters (e.g. C-reactive protein, rheumatic factor, anti citrullinated peptide, hemoglobin) or assessment of functional status (e.g. HAQ, disease activity score by 28 joints).

Conclusions: The prevalence of VD deficiency is higher in EA patients with 73% than in the general German population (vs. 60%). The prevalence of positive distress with 50% is also higher. Interestingly, no association of deficient VD levels and positive distress in the HADS was detected in our examined EA cohort. This might be explained by the early stage of disease, but further studies are necessary to evaluate this new insight.

References:

- [1] Dougados, M., et al., Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). *Ann Rheum Dis*, 2014. 73(1): p. 62–8.
- [2] Linseisen J, Bechthold A, Bischoff-Ferrari HA et al. Vitamin D und Prävention ausgewählter chronischer Krankheiten – Stellungnahme. In: V. DGfEE, ed. Bonn 2011.
- [3] Merlino LA, Curtis J, Mikuls TR, Cerhan JR, Criswell LA, Saag KG, et al. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. *Arthritis Rheum*. 2004;50(1):72–7.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2017-eular.4351

THU0140 SPECKLE TRACKING ECHOCARDIOGRAPHY EVALUATION OF CORONARY TERRITORIES IN MEXICAN MESTIZO PATIENTS WITH RHEUMATOID ARTHRITIS

D.Á. Galarza-Delgado¹, J.R. Azpiri-López², I.J. Colunga-Pedraza¹, F.J. Torres-Quintanilla², R.E. Ramos-Cázares¹, A. Valdovinos-Bañuelos¹, A. Martínez-Moreno³, R.I. Arvizu-Rivera³, R. Vera-Pineda³, J.A. Cárdenas-de la Garza³, M.A. Garza-Elizondo¹, M.A. Benavides-González², F. Hervert-Cavazos². ¹Rheumatology; ²Cardiology; ³Internal Medicine, Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico

Background: The main cause of death in patients with rheumatoid arthritis (RA) is atherosclerotic cardiovascular disease. Speckle Tracking Echocardiography (STE) is an imaging technique that analyses the local and global myocardial function by assessing the myocardial deformation (strain). This technique is useful in addressing early alterations in ischemic pathologies (1,3).

Objectives: The aim of this study was to analyze if longitudinal strain abnormalities correspond with vascular territories, and compare the results between RA-patients and matched controls.

Methods: An observational cross-section case-control study was designed. Patients that fulfilled the 1987 ACR and/or 2010 ACR/EULAR classification criteria for RA, were 40–75 years old, with no overlap syndromes and no history of atherosclerotic cardiovascular disease were included. The control group was integrated by age- and sex-matched subjects, with no rheumatologic or cardiovascular diseases. A standard transthoracic echocardiogram was performed by a